Tetrabenazine Racemate

• CAT Number: I004682
• CAS Number: 718635-93-9
• Molecular Formula: C19H27NO3
• Molecular Weight: 317.43
• Purity: ≥95%
• Target: Monoamine Transporter
• Solubility: DMSO: ≥ 3.1 mg/mL
• Storage: 3 years -20C powder
• IUPAC Name: 9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one
• InChI: InChI=1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3
• InChIKey: MKJIEFSOBYUXJB-UHFFFAOYSA-N
• SMILES: CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC

Tetrabenazine racemate（Cat No.:I004682）is a drug used to treat hyperkinetic movement disorders, such as Huntington’s disease and tardive dyskinesia. It works by depleting dopamine in the brain through the inhibition of the vesicular monoamine transporter 2 (VMAT2), which reduces abnormal movements. The racemate form consists of two mirror-image molecules, or enantiomers, which may have different pharmacological effects. Tetrabenazine is known to help manage chorea (involuntary movements) but can cause side effects, including depression, sedation, and increased risk of suicidal thoughts. Dosing and monitoring are critical to minimize adverse effects in patients.

Reference

[1]. Nunes EJ et al. Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci. 2013 Dec 4;33(49):19120-30.
[2]. Podurgiel SJ et al. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor. Neuroscience. 2013 Oct 10;250:507-19.
[3]. Reches A et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther. 1983 Jun;225(3):515-21.